About BioSight
BioSight is a Healthcare company based in Karmiel (Israel) founded in 2000, and was acquired by Advaxis in July 2021. Therapeutics for oncology and hematological disorders are developed. BioSight has raised $59 million across 3 funding rounds from investors including Migdal Group, Advaxis and The Phoenix Company. BioSight has completed 1 acquisition, including Advaxis. BioSight offers products and services including Cancer Therapeutics. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is BioSight Ltd.
Company details
BioSight was established in 2000 in Karmiel, Israel, within the biotechnology sector. Focus is placed on developing treatments for oncology and hematological conditions. The primary product, aspacytarabine (BST-236), is designed as an anti-metabolite for adult acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Operations center on advancing these therapeutic options through research and clinical development in the pharmaceutical domain.
- Headquarters Karmiel, Israel
- Stage Acquired
- SectorsHealthcare
- Website biosight-pharma.com
- Social LinkedIn
- Acquired by Advaxis (Jul 2021)
- Legal Name Biosight Ltd.
- Total Equity Funding$59M (USD)
in 3 rounds
- Latest Funding Round$27M (USD), Series C
Dec 2020
- InvestorsMigdal Group
& 8 more
- Investments & Acquisitions
- Acquired byAdvaxis
(Jul 2021)
Products & Services of BioSight
BioSight offers a comprehensive portfolio of products and services, including Cancer Therapeutics.
Innovative treatments targeting cancer through research.
Funding Insights of BioSight
BioSight has successfully raised a total of $59M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $27 million completed in December 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $59M
- Total Rounds 3
- Last Round Series C — $27M
- First Round $13M
(May 2016)
- Investors Count 8
All 3 funding rounds of BioSight with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2020 | $27M | Series C | – | Israel Biotech Fund | |
| Mar 2020 | $19M | Series C | – | Israel Biotech Fund | |
| May 2016 | $13M | Series A | – | Arkin Holdings, Primera Capital | – |
9 investors in total: 9 institutional.
Investors in BioSight
BioSight has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Migdal Group, Advaxis and The Phoenix Company.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments in technology companies are made by Primera Capital. | primeracapital.com | Oakland, United States | ||
| arkinholdings.com | ||||
| ibf.fund | ||||
| sbi-ji.co.il | ||||
Early-stage Israeli companies are invested in by Ilan Holdings. | ilan-holdings.com | Kadima, Israel | ||
Insurance coverage is provided for individuals and businesses in North Carolina. | 1932 | thephoenixcompany.com | Winston-Salem, United States | |
Insurance and financial services are offered in Israel. | 1935 | migdal.co.il | Petah Tikva, Israel | |
Remote cardiac monitoring services are provided by Philips. | myheartmonitor.com | Malvern, USA | ||
Cancer immunotherapies are developed using a proprietary Listeria-based platform. | 2002 | advaxis.com | Princeton, United States |
Investor details for BioSight
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of BioSight
10 people are tracked at BioSight (9 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
Selina M. Luger | Advisor | Board & advisors |
Jacob M. Rowe | Chairman, Clinical Advisory Board | Board & advisors |
Pierre Fenaux | Advisor | Board & advisors |
Martin S. Tallman | Advisor | Board & advisors |
Eytan M. Stein | Advisor | Board & advisors |
Gary Gordon | Director | Board & advisors |
Yuval Cabilliy | Director | Board & advisors |
Gary Titus | Director | Board & advisors |
Tsila Zuckerman | Advisor | Board & advisors |
Pini Orbach | Chairman | Team |
Complete people profiles for BioSight
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by BioSight
BioSight has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Advaxis.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Cancer immunotherapies are developed using a proprietary Listeria-based platform. | advaxis.com | Princeton, United States | 2002 | Jul 2021 | •••• |
Complete acquisition details for BioSight
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of BioSight
Web traffic of BioSight
The website of BioSight (biosight-pharma.com) receives about 1K visits a month.
- Monthly visits1K
▲ 31.3% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Biosight
Complete news archive for BioSight
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BioSight
BioSight was founded in 2000 and raised its 1st funding round 16 years after it was founded.
BioSight is headquartered in Karmiel, Israel. It is registered at Karmiel, Northern District, Israel.
BioSight is a funded company, having raised a total of $59M across 3 funding rounds to date. The company's 1st funding round was a Series A of $13M, raised on May 2016.
BioSight was established in 2000 in Karmiel, Israel, within the biotechnology sector. Focus is placed on developing treatments for oncology and hematological conditions. The primary product, aspacytarabine (BST-236), is designed as an anti-metabolite for adult acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Operations center on advancing these therapeutic options through research and clinical development in the pharmaceutical domain.
BioSight offers Cancer Therapeutics.
BioSight has made 1 acquisition, including Advaxis.
BioSight has 9 investors. Key investors include Migdal Group, Advaxis, The Phoenix Company, My Heart Monitor, and Primera Capital.
BioSight operates through Biosight Ltd..
Yes. BioSight was acquired by Advaxis in July 2021.